SABR- PSC Pilot study A single arm pilot study of Brodalumab in the treatment of Primary Sclerosing Cholangitis

A small group of patients with a rare liver disease will test a drug that blocks a specific immune signal, to see if it can be given safely and practically. This matters because primary sclerosing cholangitis (PSC) is a chronic condition where the bile ducts become inflamed and scarred, often leading to liver failure. There is no approved treatment that slows the disease. Many patients also have inflammatory bowel disease (IBD), and existing options are limited. The drug, brodalumab, inhibits a protein called IL-17 that drives inflammation in several autoimmune diseases, but its potential in PSC has not been tested in a clinical setting. If the pilot shows that brodalumab is safe, tolerable, and feasible to administer, it would open the door to a larger randomised trial. Success could eventually give patients a first-ever treatment that targets the underlying inflammation in PSC, not just its symptoms. The study also collects patient-reported outcomes and liver health markers, providing early data on whether the drug might slow liver damage. Because PSC is rare and poorly served by current medicine, even a modestly effective therapy would change clinical practice.